The data adds to mounting evidence that Zepbound and other popular GLP-1 drugs have health benefits beyond promoting weight loss and regulating blood sugar.
Eli Lilly's weight loss drug Zepbound showed benefits in patients with a common type of heart failure and obesity, according to late-stage trial data.
Patients who took Zepbound were 38% less likely to be hospitalized, need to increase their heart failure medication or die because of heart complications compared to those who received a placebo.have health benefits beyond promoting weight loss and regulating blood sugar For a median of two years, the trial followed more than 700 patients who have heart failure with preserved ejection fraction, or HFpEF, and obesity. Some patients also had diabetes.HFpEF refers to when the heart is unable to pump enough blood to meet the body's needs.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Here's why investors are selling shares of weight loss drug leader Eli LillyThe Investing Club holds its 'Morning Meeting' every weekday at 10:20 a.m. ET.
Read more »
FDA approves new Alzheimer's treatment, donanemab from Eli LillyFDA approval of the new Alzheimer's treatment, which will be branded as Kisunla, follows years of setbacks.
Read more »
FDA approves Eli Lilly's Alzheimer’s drug that slows memory declineBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
FDA approves Eli Lilly Alzheimer's drug, expanding treatment options in U.S.Donanemab will compete head-to-head with another treatment from Biogen and its Japanese partner Eisai called Leqembi
Read more »
US FDA approves Eli Lilly Alzheimer's drug that slows progress of the diseaseThe U.S. Food and Drug Administration on Tuesday gave a green light to Eli Lilly’s LLY.N donanemab for patients with early Alzheimer’s, making it the second approved drug for slowing th…
Read more »
FDA approves Eli Lilly’s Alzheimer’s drug KisunlaBerkeley Lovelace Jr. is a health and medical news reporter for NBC News.
Read more »